January 30th 2024
William G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.
March 14th 2022
Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.
March 7th 2022
A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
February 28th 2022
What to know in terms of COVID-19 vaccine responses in patients with chronic lymphocytic leukemia on novel targeted therapies.
Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.
February 21st 2022
Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).
Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.
February 14th 2022
Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.
The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.
February 7th 2022
Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.
Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
January 31st 2022
An overview of safety and efficacy data for a third-generation Bruton tyrosine kinase inhibitor, zanubrutinib, as treatment for patients with chronic lymphocytic leukemia.
Features that distinguish acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, from ibrutinib as frontline therapy for patients with chronic lymphocytic leukemia.
January 24th 2022
Reactions to longer-term follow-up data presented in 2021 on the use of ibrutinib as frontline treatment for patients with chronic lymphocytic leukemia.
The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.
October 25th 2021
William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.
October 21st 2021
William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.
September 23rd 2021
William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.